Hyperpigmentation Disorder Treatment Market Scope And Analysis

Report Code : TIPRE00029977
Category : Life Sciences

Status : Published
No. of Pages : 158

Buy Now

Hyperpigmentation Disorder Treatment Market Analysis, Scope, and Growth by 2030

Buy Now

Hyperpigmentation Disorder Treatment Market Report Scope

Report Attribute	Details
Market size in 2022	US$ 6.68 Billion
Market Size by 2030	US$ 11.78 Billion
Global CAGR (2022 - 2030)	7.4%
Historical Data	2021-2022
Forecast period	2024-2031
Segments Covered	By Treatment Type Cosmeceutical Light or Laser Therapy Microdermabrasion Chemical Peels Cryotherapy By Condition Melasma Solar Lentigines Post-Inflammatory Hyperpigmentation By End User Hospitals Dermatology Centers
Regions and Countries Covered	North America US Canada Mexico Europe France Germany UK Spain Italy Rest of Europe Asia Pacific China Japan India Australia South Korea Rest of Asia Pacific Middle East and Africa Saudi Arabia UAE South Africa Rest of Middle East and Africa and South and Central America Brazil Argentina Rest of South and Central America
Market leaders and key company profiles	AbbVie Inc Bayer AG Epipharm AG Galderma Laboratories Obagi Cosmeceuticals LLC Lutronic Corporation La Pristine L oreal S A Pierre Fabre Group Vivier Pharma USA

Industry Developments and Future Opportunities:

A few of the strategic developments by leading players operating in the hyperpigmentation disorder treatment market, as per company press releases, are listed below:

In February 2024, L'Oréal Paris launched the Glycolic Bright Dark Circle Eye Serum, a groundbreaking solution for under-eye hyperpigmentation and puffiness. The serum, formulated with a blend of 3% glycolic acid, vitamin CG, and niacinamide, promises to diminish dark circles by 49% in just 2 weeks. The serum is ophthalmologically tested, suitable for all skin types, and clinically proven to treat visible dark circles.
In October 2023, Galderma expanded its skincare brand Alastin in two important markets—Canada and the UK. Galderma announced its plans to directly distribute Alastin in Canada and launch the brand in the UK. Galderma's Aesthetics business expansion in both of these markets would boost the awareness of Alastin and help drive its adoption by healthcare professionals and consumers.
In January 2023, Allergan Aesthetics, a subsidiary of AbbVie company, launched SkinMedica Even & Correct Collection. The product line consisting of three products—Advanced Brightening Treatment, Dark Spot Cream, and Brightening Treatment Pads—is formulated to deliver targeted results, and work together to even skin tone and reduce the appearance of hyperpigmentation and dark spots on the face.

Competitive Landscape and Key Companies:

AbbVie Inc, Bayer AG, Epipharm AG, Galderma Laboratories, Obagi Cosmeceuticals LLC, Lutronic Corporation, La Pristine, L’oreal S.A, Pierre Fabre Group, and Vivier Pharma USA are among the prominent companies profiled in the hyperpigmentation disorder treatment market report. These companies focus on developing new technologies, upgrading existing products, and expanding their geographic presence to meet the growing consumer demand worldwide.